文献速递胸部肿瘤

PACIFIC事后分析:基线PPI与抗生素对III期NSCLC免疫治疗疗效的差异影响

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.
PubMed 文献 · Lancet Oncol · 2026-07-03

该研究为PACIFIC试验事后分析,纳入660例不可切除III期NSCLC患者,评估基线质子泵抑制剂(PPI)和抗生素暴露与度伐利尤单抗疗效的关系。结果显示,在度伐利尤单抗组中,基线PPI暴露与更短的无进展生存期(PFS)和总生存期(OS)相关,基线抗生素暴露与更短PFS相关但OS无显著差异;安慰剂组中未见此关联。

要点

  • 度伐利尤单抗组基线PPI暴露者PFS和OS均显著缩短。
  • 度伐利尤单抗组基线抗生素暴露者PFS缩短,但OS无显著差异。
  • 安慰剂组中PPI或抗生素暴露与PFS和OS无显著关联。

核心结论

  • 在不可切除III期NSCLC患者中,基线PPI和抗生素暴露与度伐利尤单抗疗效降低相关,而与安慰剂组无此关联。

研究设计与样本

  • PACIFIC为随机双盲安慰剂对照3期试验,患者随机(2:1)接受度伐利尤单抗10 mg/kg每2周最多12个月或安慰剂。
  • 本事后分析纳入660例接受治疗并同意探索性分析的患者,其中度伐利尤单抗组449例,安慰剂组211例。

主要发现

  • 安慰剂组中,PPI或抗生素暴露与PFS和OS均无显著关联。

临床怎么用

  • 在III期NSCLC接受度伐利尤单抗巩固治疗前,应评估并审慎管理基线PPI和抗生素的使用。

局限性

  • 本分析为事后分析,可能存在未控制的混杂因素。
  • 抗生素暴露患者样本量较小(69例),结果解释需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Baseline exposure to antibiotics and proton pump inhibitors has been associated with reduced efficacy of immune checkpoint inhibitors in patients with advanced tumours, possibly through gut microbiome disruption. Whether this outcome extends to those with earlier-stage disease remains unclear. We aimed to assess the association of baseline antibiotics and proton pump inhibitors with progression-free survival and overall survival in patients with unresectable stage III non-small cell lung cancer (NSCLC). METHODS: PACIFIC was a randomised, double-blind, placebo-controlled phase 3 trial done in patients aged 18 years or older with unresectable stage III squamous or non-squamous NSCLC, WHO performance status 0-1, and no progression after two or more cycles of concurrent chemoradiotherapy. Patients were randomly assigned (2:1) to durvalumab 10 mg/kg intravenously every 2 weeks for up to 12 months or placebo, starting 1-42 days after chemoradiotherapy; patients were stratified by age, sex, and smoking history. This post-hoc analysis was based on the final 5-year data cutoff date of the completed trial and included the treated population with consent for exploratory analyses. Co-primary endpoints were progression-free survival and overall survival, assessed according to baseline exposure to proton pump inhibitors and systemic antibiotics. This trial is registered on ClinicalTrials.gov (NCT02125461). FINDINGS: Between May 9, 2014, and April 22, 2016, 713 patients were randomly assigned; 660 were included in this post-hoc analysis, of whom 449 received durvalumab and 211 received placebo; 203 (30·8%) were female and 453 (68·6%) were male. Race was reported as Asian in 153 (23·1%) patients, Black or African American in five (0·7%), White in 424 (64·2%), and unknown in 78 (11·8%). Baseline proton pump inhibitor exposure was recorded in 263 (40%) of 660 patients and antibiotic exposure was recorded in 69 (10%). Median follow-up in the pooled population was 62·4 (IQR 61·9-63·2) months. In the durvalumab group baseline exposure to proton pump inhibitors was associated with shorter progression-free survival (9·4 months [95% CI 7·6-13·7] vs 17·2 months [15·4-23·2]; hazard ratio [HR] 1·57 [95% CI 1·28-1·93]; p<0·0001) and overall survival (33·0 months [95% CI 21·9-46·7] vs 57·9 months [48·7-not computable (NC)]; HR 1·66 [95% CI 1·30-2·13]; p<0·0001) compared to no exposure to proton pump inhibitors, while baseline exposure to antibiotics was associated with shorter progression-free survival (9·2 months [95% CI 4·9-18·1] vs 15·6 months [13·6-17·6]; HR 1·50 [95% CI 1·08-2·10]; p=0·016) compared to no exposure to antibiotics, but there was no significant change in overall survival (37·7 months [95% CI 18·8-NC; 28 events] vs 49·2 months [39·7-57·3]; HR 1·33 [95% CI 0·90-1·97]; p=0·16). In the placebo group, neither proton pump inhibitor exposure nor antibiotic exposure was associated with changes in progression-free survival and overall survival. Interactions between treatment and proton pump inhibitors for progression-free survival (p=0·023) and overall survival (p<0·0001) were significant, but not for antibiotics. INTERPRETATION: Baseline exposure to proton pump inhibitors and antibiotics was associated with inferior outcomes with durvalumab, but not with placebo, consistent with potential attenuation of the benefit of durvalumab with proton pump inhibitors and antibiotics in patients with unresectable stage III NSCLC. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Brunetti L, Santo V, Pinato DJ, et al. Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial. Lancet Oncol. 2026. PMID: 42398520. doi:10.1016/S1470-2045(26)00191-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。